The Oligonucleotide Therapeutics Society (OTS) is an open, nonprofit forum to foster research and development of oligonucleotide therapeutics. The Founders’ vision was to bring together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential. A new era of oligonucleotide drugs was envisioned that would change the landscape of therapeutic modalities.
Oligonucleotide therapeutics are now being used to successfully treat diseases and have the potential for widespread application. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. Incredibly, oligonucleotide therapeutics have also been used to create an individualized treatment for one single person with a rare, fatal disease.
All the latest news
OTS Statement on Recent Supreme Court Decision
The Leadership of the Oligonucleotide Therapeutics Society (OTS) recognizes that many of our members are concerned by the recent United [...]
CRISPR Patent Rights and Their Effect on the Industry
A decade ago, Jennifer Doudna of the University of California, Berkley and Emmanuelle Charpentier of the Max Planck Institute [...]
Could Artificial Intelligence Provide the Key to Life Saving Medicines?
Drug discovery is time consuming and expensive, requiring trial and error screening. This means that many people have to [...]
Featured Member
M.Sc. Philipp Niklas Ostermann
PhD Student
Heiner Schaal Lab
Institute of Virology
University Hospital Düsseldorf
I have to say that since the first semesters of my Bachelor’s studies in general biology, I wanted to become a molecular virologist. Hence, I ended up working with antisense oligonucleotides by chance. However, I directly liked the idea to tackle viral disease by disturbing different steps of viral RNA processing as this offers a promising and very specific way to inhibit viral replication.
;
